Review ArticlesImmune and Cell Therapy in Non-Hodgkin LymphomaMerryman, Reid W. MD∗; Houot, Roch MD∗,†; Armand, Philippe MD, PhD∗; Jacobson, Caron MD∗Author Information From the ∗Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA †Department of Hematology, CHU de Rennes, Université de Rennes, INSERM U1236, Rennes, France. Reprints: Reid W. Merryman, MD, 450 Brookline Ave Boston, MA 02215. E-mail: email@example.com. Conflicts of Interest and Source of Funding: R.W.M. has none declared. R.H. receives/received honoraria or consulting fees from Bristol-Myers Squibb, MSD, Gilead, Kite, Roche, Novartis, Janssen, and Celgene. P.A. is/was consultant to Merck, BMS, Pfizer, Affimed, Adaptive, Infinity, ADC Therapeutics, Celgene, Morphosys, Daiichi Sankyo, and Miltenyi; receives/received institutional research funding from Merck, BMS, Affimed, Adaptive, Roche, Tensha, Otsuka, Sigma Tau, Genentech, and IGM; and receives/received honoraria from Merck and BMS. C.J. is/was consultant to Kite, Novartis, Celgene, Precision Biosciences, Humanigen, and Nkarta and receives/received research funding from Pfizer. The Cancer Journal: 5/6 2020 - Volume 26 - Issue 3 - p 269-277 doi: 10.1097/PPO.0000000000000445 Buy Metrics Abstract The promise of immunotherapy has shone brightly for decades in hematologic malignancies and specifically in non-Hodgkin lymphoma. The last decade has witnessed the emergence of completely novel forms of immunotherapy, including immune checkpoint blockade, bispecific antibodies, and chimeric antigen receptor T cells. These treatments have shown phenomenal, and in some cases possibly curative, successes in various relapsed/refractory lymphomas. This review summarizes the most notable successes and promising findings as well as some of the attendant failures. These treatments will doubtlessly transform the treatment paradigms across many lymphoma subtypes. Yet, only if we can better understand their mechanisms of action, toxicity, and resistance will be able to maximize their therapeutic benefit. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.